You are here

  • Home
  • Archive
  • Volume 10, Issue 8
  • Cost-effectiveness analysis of cinacalcet for haemodialysis patients with moderate-to-severe secondary hyperparathyroidism in China: evaluation based on the EVOLVE trial

Citation Tools

Article menu

Download PDFPDF

XML
Health economics
Original research
Cost-effectiveness analysis of cinacalcet for haemodialysis patients with moderate-to-severe secondary hyperparathyroidism in China: evaluation based on the EVOLVE trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Liu L, Hong D, Ma K, et al
Cost-effectiveness analysis of cinacalcet for haemodialysis patients with moderate-to-severe secondary hyperparathyroidism in China: evaluation based on the EVOLVE trial
BMJ Open 2020;10:e034123. doi: 10.1136/bmjopen-2019-034123